ALK and non-small cell lung carcinoma: In addition, although crizotinib, initially designed as a MET inhibitor, is FDA-approved for ALK-rearranged NSCLC patients, it has shown activity in a subgroup of NSCLC patients that lack an ALK translocation but overexpress MET, or carrying de novo MET gene amplification [20–22].